论文部分内容阅读
目的分析卡维地洛治疗高血压合并糖尿病患者心率失常临床效果与安全性。方法 92例高血压合并糖尿病患者,随机分为实验组与对照组,每组46例。对照组给予常规治疗,实验组在常规治疗基础上给予卡维地洛治疗。观察两组治疗后的舒张压(DBP)、收缩压(SBP)、空腹血糖(FBG)及心率(HR)等指标变化情况,并比较两组患者不良反应情况。结果经治疗,实验组DBP、HR及SBP指标分别为(84.56±6.57)mm Hg(1 mm Hg=0.133 k Pa)、(85.76±4.28)次/min、(138.83±11.47)mm Hg,均优于对照组的(71.24±6.03)mm Hg、(72.48±2.36)次/min、(121.39±9.58)mm Hg(P<0.05);两组FBG、不良反应发生率比较差异无统计学意义(P>0.05)。结论给予高血压合并糖尿病患者卡维地洛治疗心律失常可取得显著临床疗效,保持较高安全性,值得临床推广。
Objective To analyze the clinical effect and safety of carvedilol in treating patients with hypertension and diabetes mellitus. Methods A total of 92 hypertensive patients with diabetes mellitus were randomly divided into experimental group and control group, with 46 cases in each group. The control group was given routine treatment, and the experimental group was treated with carvedilol on the basis of routine treatment. The changes of DBP, SBP, FBG and heart rate (HR) were observed after treatment. The adverse reactions of the two groups were compared. Results After treatment, the indexes of DBP, HR and SBP in the experimental group were (84.56 ± 6.57) mm Hg (1 mm Hg = 0.133 k Pa), (85.76 ± 4.28) / min and (138.83 ± 11.47) mm Hg, respectively (71.24 ± 6.03) mm Hg, (72.48 ± 2.36) / min, (121.39 ± 9.58) mm Hg in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusions The treatment of arrhythmia with carvedilol in patients with hypertension and diabetes mellitus can achieve significant clinical effect, maintain high safety and worthy of clinical promotion.